Clinical and economic burden of pneumococcal disease in older US adults
| Autor: | John Edelsberg, Reiko Sato, David R. Strutton, Derek Weycker, Lisa A. Jackson |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
Pneumococcal disease Pneumococcal Infections Indirect costs Cost of Illness Epidemiology medicine Humans Aged Aged 80 and over General Veterinary General Immunology and Microbiology business.industry Public Health Environmental and Occupational Health Bacterial pneumonia Middle Aged medicine.disease United States Vaccination Pneumonia Pneumococcal infections Models Economic Infectious Diseases Pneumococcal pneumonia Immunology Costs and Cost Analysis Molecular Medicine Health Expenditures business Demography |
| Zdroj: | Vaccine. 28:4955-4960 |
| ISSN: | 0264-410X |
| Popis: | We developed a model characterizing rates and costs of pneumococcal disease in the US to estimate the expected annual clinical and economic burden of this condition among older adults. Among the 91.5 million US adults aged >or=50 years, 29,500 cases of invasive pneumococcal disease, 502,600 cases of nonbacteremic pneumococcal pneumonia, and 25,400 pneumococcal-related deaths are estimated to occur yearly; annual direct and indirect costs are estimated to total $3.7 billion and $1.8 billion, respectively. Pneumococcal disease remains a substantial burden among older US adults, despite increased coverage with PPV23 and indirect benefits afforded by PCV7 vaccination of young children. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect